Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Centricsbio Inc. manages a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. There is 1 pending office action currently active. This prosecution is limited to 1 distinct examiner, suggesting a focused approach to the company's current intellectual property matters. The portfolio is active in 1 distinct art unit, which defines the technical scope of the pending review.
BERHANE, SELAM is the busiest examiner for the portfolio, responsible for 1 busiest examiner pending office action. This action accounts for the total 1 pending office action for the company. For a practitioner, this means that the prosecution strategy should be specifically adapted to this examiner's requirements. The data shows that the company's current interactions with the patent office are concentrated in a single examiner and art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BERHANE, SELAM | 1 | 59.1% | +56.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17746569 | ANTI-CD300C MONOCLONAL ANTIBODY AND BIOMARKER THEREOF FOR PREVENTING OR TREATING CANCER | BERHANE, SELAM | — |
| Art Unit | Apps |
|---|---|
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17746569 | ANTI-CD300C MONOCLONAL ANTIBODY AND BIOMARKER THEREOF FOR PREVENTING OR TREATING CANCER | BERHANE, SELAM | 1675 | §112 | Non-Final OA | — | Pending | May 17, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCentricsbio Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Selam Berhane has the most, with 1 of Centricsbio Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
